Literature DB >> 16395672

Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations.

Ewy Mathe1, Magali Olivier, Shunsuke Kato, Chikashi Ishioka, Iosif Vaisman, Pierre Hainaut.   

Abstract

We describe a novel statistical scoring method based on a computational geometry approach to predict the functional impact (transactivation activity) of missense mutations in the DNA-binding domain (DBD) of the tumor suppressor TP53, which is the most frequently mutated gene in human cancer. Residual scores (RS) for each residue were calculated to reflect differences in the compositional preferences of four nearest-neighbor residues between mutant and wild-type proteins. The RS were then combined into a residual score profile (RSP) representing the RS values for all 194 residues in the DBD. Mutants were grouped into functional categories based on their transactivation activities experimentally measured in yeast functional assays using p53-response elements from eight different promoters. While these functional categories showed significant differences in average RS, the latter lacked resolution power to predict the transactivation activities of individual mutants. In contrast, using decision tree models, we found that the RSP predicted transactivation with an accuracy varying between 64.2% and 78.5% depending on the promoter. Lastly, we used the best model to predict the functional outcome of all missense mutants in the DBD of p53 and compared the predictions with their frequency of occurrence in human cancers. We found that mutants predicted as functional (F) accounted for approximately 14% of all missense mutants found in cancers, while mutants predicted as nonfunctional (NF) represented approximately 86% of the mutants. These results show that this computational approach provides a fast and reliable method for predicting the functional impact of p53 mutants associated with cancer. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395672     DOI: 10.1002/humu.20284

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

1.  Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.

Authors:  Jennifer J Jordan; Alberto Inga; Kathleen Conway; Sharon Edmiston; Lisa A Carey; Lin Wu; Michael A Resnick
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

2.  Somatic alterations in brain tumors.

Authors:  Jill Barnholtz-Sloan; Andrew E Sloan; Susan Land; William Kupsky; Alvaro N A Monteiro
Journal:  Oncol Rep       Date:  2008-07       Impact factor: 3.906

3.  Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.

Authors:  Xiaoli Ma; Vanessa Rousseau; Haiji Sun; Sylvie Lantuejoul; Martin Filipits; Robert Pirker; Helmut Popper; Jean Mendiboure; Anne-Lise Vataire; Thierry Le Chevalier; Jean Charles Soria; Elisabeth Brambilla; Ariane Dunant; Pierre Hainaut
Journal:  Mol Oncol       Date:  2014-01-15       Impact factor: 6.603

4.  The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12.

Authors:  Shuting Jia; Lanjun Zhao; Wenru Tang; Ying Luo
Journal:  Int J Biol Sci       Date:  2012-04-18       Impact factor: 6.580

5.  Functional impact of missense variants in BRCA1 predicted by supervised learning.

Authors:  Rachel Karchin; Alvaro N A Monteiro; Sean V Tavtigian; Marcelo A Carvalho; Andrej Sali
Journal:  PLoS Comput Biol       Date:  2006-12-28       Impact factor: 4.475

6.  Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer.

Authors:  Vahinipriya Manoharan; Eric Hamilton Karunanayake; Kamani Hemamala Tennekoon; Sumadee De Silva; Kanishka De Silva; Preethika Angunawela; John Lunec
Journal:  Mol Med Rep       Date:  2019-02-11       Impact factor: 2.952

7.  Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.

Authors:  Barbara Wappenschmidt; Jan Hauke; Ulrike Faust; Dieter Niederacher; Lisa Wiesmüller; Gunnar Schmidt; Evi Groß; Andrea Gehrig; Christian Sutter; Juliane Ramser; Andreas Rump; Norbert Arnold; Alfons Meindl
Journal:  Geburtshilfe Frauenheilkd       Date:  2020-04-21       Impact factor: 2.915

8.  A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancer.

Authors:  Yonggeun Cho; Juwon Kim; Yoonjung Kim; Joon Jeong; Kyung-A Lee
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

9.  Prediction of P53 mutants (multiple sites) transcriptional activity based on structural (2D&3D) properties.

Authors:  R Geetha Ramani; Shomona Gracia Jacob
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.